ArticleFrontiers in oncology2025
Antiproliferative and pro-apoptotic effects of
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mammary gland malignancies are the most diagnosed oncological diseases in women. The currently available treatment faces several problems, including resistance to cytostatics and the relatively high recurrence rates. These limitations have led to an increasing interest in natural substances as potential anticancer agents. Therapeutic approaches using a combination of natural anticancer agent and conventional cytostatic drug could also be beneficial in minimising the risk of chemotherapy. In the present study, we evaluated the anticancer effect of Methods: To investigate the effects of tested compounds, a range of assays were employed. BrdU and clonogenic assays were used to evaluate antiproliferative activity. Flow cytometry and Western blot were used to demonstrate apoptotic cell death, oxidative stress, DNA damage, and immune checkpoint modulation in a time-dependent manner (24, 48, and 72 h). Results: PSE and PHY induced cycle arrest at a G1 checkpoint with modulation of cell cycle-related proteins. Furthermore, activation of intrinsic apoptotic pathway, involving changes in Bcl-2 family proteins, caspase-3/-7 activity, caspase-9 cleavage, cytochrome Conclusions: Treatment with PSE and PHY in BC cells resulted in mitochondrial apoptosis associated with oxidative stress and DNA damage. Furthermore, modulation of immune checkpoint PD-1/PD-L1 was demonstrated. Based on the results, we assume the use of PSE and PHY as promising targeted agents for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.